MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$68,058K
Free Cash flow
-$70,639K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation expense
Revenue
Interest income
Others
Negative Cash Flow Breakdown
Axpaxli
Selling and marketing
General and administrative
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Revenue
13,475
10,785
13,250
38,701
Cost of product revenue
2,011
1,329
1,594
4,980
Axpaxli
28,756
42,460
26,716
92,893
Direct program expenses, axpaxli for npdr
-
-
4,804
-
Direct program expenses, other clinical and preclinical programs
717
758
275
3,307
Unallocated expenses, personnel costs
13,538
12,976
11,430
27,825
Unallocated expenses, all other costs
2,081
1,809
1,541
5,986
Selling and marketing
15,078
14,075
11,538
36,972
General and administrative
14,416
11,606
10,513
26,864
Facilities
2,488
2,270
1,993
5,230
Stock-based compensation
14,649
15,582
11,359
31,825
Depreciation
1,851
1,260
1,247
3,076
Interest income
5,450
6,050
7,343
11,012
Interest expense
2,792
2,777
2,832
9,003
Other non-operating items
689
1,455
595
-3,037
Net loss
-78,763
-88,612
-64,654
-69,418
Stock-based compensation expense
14,649
15,582
11,359
11,691
Non-cash interest expense
640
1,381
495
758
Change in fair value of derivative liabilities
689
1,455
595
-1,447
Depreciation and amortization expense
1,851
1,283
1,247
1,069
Loss on disposal of items of property and equipment
-
-4,866
0
0
Loss (gain) on disposal of items of property and equipment
-4,866
-
-
-
Accounts receivable, net
5,914
-6,303
-118
356
Prepaid expenses and other current assets
487
357
2,903
-522
Inventory
89
173
76
449
Accounts payable
196
3,719
-1,353
-1,272
Operating lease assets
-675
1,857
-696
-549
Accrued expenses
1,471
-8,441
2,176
5,376
Deferred revenue
-
-
0
0
Operating lease liabilities
-812
1,768
-759
-642
Net cash used in operating activities
-67,272
-65,993
-54,249
-50,725
Purchases of property and equipment
3,367
4,662
2,839
5,993
Proceeds from sales of property and equipment
-
-
0
0
Net cash used in investing activities
-3,367
-4,662
-2,839
-5,993
Proceeds from exercise of stock options
1,679
294
2,937
10,356
Proceeds from issuance of common stock pursuant to employee stock purchase plan
902
-
879
0
Proceeds from issuance of common stock upon public offering, net of issuance costs
-
-
445,560
0
Net cash provided by financing activities
2,581
294
449,376
10,356
Net decrease in cash, cash equivalents and restricted cash
-68,058
-70,361
392,288
-46,362
Cash, cash equivalents and restricted cash at beginning of period
668,313
738,674
346,386
393,716
Cash, cash equivalents and restricted cash at end of period
600,255
668,313
738,674
346,386
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from exercise of
stock options
$1,679K
(-76.84%↓ Y/Y)
Proceeds from issuance of
common stock pursuant...
$902K
(26.51%↑ Y/Y)
Net cash provided by
financing activities
$2,581K
(-97.47%↓ Y/Y)
Net decrease in
cash, cash...
-$68,058K
(-6930.79%↓ Y/Y)
Canceled cashflow
$2,581K
Stock-based compensation
expense
$14,649K
(-27.24%↓ Y/Y)
Loss (gain) on
disposal of items of...
-$4,866K
Depreciation and
amortization expense
$1,851K
(-7.77%↓ Y/Y)
Accrued expenses
$1,471K
(163.85%↑ Y/Y)
Operating lease assets
-$675K
(-988.71%↓ Y/Y)
Non-cash interest
expense
$640K
(-70.15%↓ Y/Y)
Accounts payable
$196K
(-88.72%↓ Y/Y)
Net cash used in
operating activities
-$67,272K
(32.67%↑ Y/Y)
Net cash used in
investing activities
-$3,367K
(-10.47%↓ Y/Y)
Canceled cashflow
$24,348K
Revenue
$13,475K
Interest income
$5,450K
Other non-operating
items
$689K
Net loss
-$78,763K
(40.27%↑ Y/Y)
Purchases of property and
equipment
$3,367K
(5.95%↑ Y/Y)
Canceled cashflow
$19,614K
Accounts receivable, net
$5,914K
(399.29%↑ Y/Y)
something is missing
-$4,866K
Operating lease
liabilities
-$812K
(-231.43%↓ Y/Y)
Change in fair value of
derivative liabilities
$689K
(142.56%↑ Y/Y)
Prepaid expenses and
other current assets
$487K
(109.77%↑ Y/Y)
Inventory
$89K
(9000.00%↑ Y/Y)
Axpaxli
$28,756K
Selling and marketing
$15,078K
Stock-based compensation
$14,649K
General and
administrative
$14,416K
Unallocated expenses,
personnel costs
$13,538K
Interest expense
$2,792K
Facilities
$2,488K
Unallocated expenses, all
other costs
$2,081K
Cost of product
revenue
$2,011K
Depreciation
$1,851K
Direct program
expenses, other clinical...
$717K
Buy us a coffee
OCULAR THERAPEUTIX, INC (OCUL)
OCULAR THERAPEUTIX, INC (OCUL)